National Heart, Lung, and Blood Institute (NHLBI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Heart, Lung, and Blood Institute (NHLBI) sits in the top decile of US sponsors by registered trial count (#73 of 15,742 sponsors by registered trial count).
National Heart, Lung, and Blood Institute (NHLBI): 501 sponsored US clinical trials, 62 recruiting.
National Heart, Lung, and Blood Institute (NHLBI) sponsors 501 registered US clinical trials on ClinicalTrials.gov, 62 of them currently recruiting, and 381 completed. 33 of these trials are in Phase 3-4 (later-stage) and 205 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Atherosclerosis, with 12 trials.
Top-decile sponsor footprint
National Heart, Lung, and Blood Institute (NHLBI) ranks in the top decile of sponsors by registered trial count (#73 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
381 of 417 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
501 total, page 10 of 11
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
NCT00001637
Safety and Effectiveness of Coronary Magnetic Resonance Angiography (CMRA) Imaging
NCT00001633
Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease
NCT00001632
Study of Blood Flow in Heart Muscle
NCT00001631
Treatment of Autoimmune Thrombocytopenia (AITP)
NCT00001630
Collection of Blood and Bone Marrow From Healthy Volunteers and Patients for Research Purposes
NCT00001627
The Role of Angiotensin Type I Receptor in the Regulation of Human Peripheral Vascular Function
NCT00001628
The Role of Angiotensin Type I Receptor in the Regulation of Human Coronary Vascular Function
NCT00001629
Comparing Therapies for the Treatment of Severe Aplastic Anemia
NCT00001626
Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia
NCT00001623
Study of the Response of Human Small Blood Vessels
NCT00001622
Effect of Insulin on Endothelin-Dependent Vascular Tone in the Forearm Circulation
NCT00001624
Evaluation and Treatment of Patients With Lung Disease Not Participating in Research
NCT00001621
Segmental Bronchoalveolar Lavage
NCT00001618
Magnetic Resonance Imaging at Different Levels of Magnetic Intensity
NCT00001619
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine
NCT00001533
Long Term Effects of Enalapril and Losartan on Genetic Heart Disease
NCT00001534
Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction
NCT00001531
Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy
NCT00001530
Analysis of Heart Muscle Function Following Exercise in Patients With Heart Disease
NCT00001528
The Women's Health Initiative Memory Study (The WHIMS Study)
NCT00685009
Role of Endothelin in the Regulation of Vascular Tone in Patients With Essential Hypertension
NCT00001527
Effect of High Levels of Oxygen and Smoking on the Lungs in Human Volunteers
NCT00001464
Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals
NCT00001462
Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme
NCT00001461
Evaluation of Patients With Heart Disease Not Eligible for Research Protocols
NCT00001458
Evaluation and Treatment of Heart Disease in Patients Not Participating in Research
NCT00001460
Analysis of Heart Muscle Function in Patients With Heart Disease and Normal Volunteers
NCT00001459
Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)
NCT00000579
PET Scan to Determine Areas of Blood Flow and Activity in the Hearts of Patients With Heart Disease Taking Beta-Blockers
NCT00001402
Gene Therapy for the Treatment of Fanconi's Anemia Type C
NCT00001399
Outpatient Evaluation of Patients With Known or Suspected Heart Disease
NCT00001400
Evaluation, Treatment, and Training for Patients With Blood Disorders
NCT00001397
Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop...
NCT00001396
Stem Cell Factor Medication for Aplastic Anemia
NCT00001398
Evaluation of Patients With Known or Suspected Heart Disease
NCT00001313
Investigation of Heart Function in Patients With Heart Valve Defects
NCT00001314
Trial of Nonpharmacologic Interventions in Elderly (TONE)
NCT00000535
Cardiovascular Evaluation of Patients With High Cholesterol and Normal Volunteers
NCT00001204
Diagnosis and Treatment of Pheochromocytoma
NCT00001229
Lipoprotein Metabolism in Normal Volunteers and Patients With Abnormal Levels of Lipoproteins
NCT00001226
Family Studies of Inherited Heart Disease
NCT00001225
Collection of Blood From Patients With Pancytopenia
NCT00001214
Deferoxamine for the Treatment of Hemochromatosis
NCT00001203
Evaluating Electrocardiogram (ECG) Abnormalities From Young Adulthood Through Middle Age
NCT00556751
Evaluation of the Causes and Disease Processes of Chronic Lung Disease
NCT00001183
Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia
NCT00001197
Effects of Salt Intake on the Nervous Systems of Patients With Salt-Sensitive High Blood Pressure
NCT00001176
Evaluation of Lipoproteins
NCT00001168
Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
NCT00001154
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 87 |
| Phase 2 | 118 |
| Phase 3 | 29 |
| Phase 4 | 4 |
Therapeutic Areas
What is open in the National Heart, Lung, and Blood Institute (NHLBI) pipeline
62 recruiting of 501 indexed (12% open); 381 completed (76%).
Phase mix: 33 late (III/IV) vs 205 early (I/II) (early-phase heavy).
Top condition: Atherosclerosis (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Heart, Lung, and Blood Institute (NHLBI): open-pipeline peers nationwide
Peers matched on 501 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
National Heart, Lung, and Blood Institute (NHLBI) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 501 trials (± recruiting share)
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
- Gilead Sciences · 504 trials · 5% recruiting
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 490 trials · 10% recruiting
- Beth Israel Deaconess Medical Center · 488 trials · 14% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Boston University · 12% recruiting · 185 trials
- AstraZeneca · 12% recruiting · 1,285 trials
- Daiichi Sankyo · 12% recruiting · 236 trials
- University of Iowa · 12% recruiting · 228 trials
Related
What to do with this National Heart, Lung, and Blood Institute (NHLBI) page
501 registered trials is a research-attention snapshot, not an endorsement of National Heart, Lung, and Blood Institute (NHLBI) or any single study.
- 62 of National Heart, Lung, and Blood Institute (NHLBI)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Atherosclerosis is the condition National Heart, Lung, and Blood Institute (NHLBI) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Atherosclerosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Heart, Lung, and Blood Institute (NHLBI) pipeline card: 501 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.